MONTREAL – Researchers at McGill University in Montreal say recent research rejects the hypothesis that anti-inflammatory drugs can help stop Alzheimer's disease progression.
The school tested the effect of inflammation of the 200 participants who were at risk of developing the disease but did not yet show any symptoms.
The authors of the study say that a two-year clinical study did not show that taking a regular drug, sold under the Ace brand, had an impact on the progression of the disease compared to placebo.
The school says scientists have known for decades that Alzheimer's disease has been associated with inflammation, leading to hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) can help stop or prevent the disease.
But researchers say the following clinical trials point to the conclusion that drugs do not make a difference, regardless of whether patients have already experienced cognitive impairment.
Dr John Breitner, the lead author, says the findings suggest that researchers will have to look elsewhere to look for a way to prevent disease.